

亚和

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86357

Tetsuro KIKUCHI, et al.

Appln. No.: 10/540,577

Group Art Unit: 1614

Confirmation No.: 6428

Examiner: Not Yet Assigned

Filed: June 24, 2005

For:

CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR

TREATMENT OF MOOD DISORDERS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the listed U.S. patent publication.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.:10/540,577

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 32,765

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: February 21, 2006

2

				MODITIED 1 10/3B/08 A & B (00-03)		
Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY A PRI LOAD OF THE PRINT BY A PRI LOAD OF THE PRI LOAD OF THE PRINT BY A PRI LOAD OF THE PRI LOAD OF THE PRI LOAD OF THE PRINT BY A PRI LOAD OF THE PRI LOAD OF THE PRINT BY A PRI LOAD OF THE PRINT BY A PRI LOAD OF THE PRI LOAD OF THE PRI LOAD OF THE PRINT BY A PRI LOAD OF THE PRI LOAD OF THE PRINT BY A PRINT BY A PRI LOAD OF THE PRINT BY A PRINT BY A PRINT BY A PRINT BY A PRI LOAD OF THE PRINT BY A PRI		Complete if Known				
		Application Number	10/540,577			
INFOR	MATION	DISCLOSURE	Confirmation Number	6428		
STATEMENT BY APPLICANY			Filing Date	June 24, 2005		
			First Named Inventor	Tetsuro KIKUCHI		
(use as many sheets as necessary) FEB 2 1 2006			Art Unit	1614		
			Examiner Name			
Sheet	1	of 🐧	Attorney Docket Number	Q86357		
MADENA						

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	Document Number		Publication Date			
	No.1	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US 2005/0038015	A1	02/17/2005	Bronzova et al		
		US					
		US					
		US					
		US					
		US	Ĭ				
		US					
		US	Ì				
		US					

FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials* No.1	Foreign Patent Document			Publication Date	Name of Patentee or		
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
	·	wo	03/068207	A2 and A3	08/21/2003	Solvay Pharmaceuticals B.V.	
		<u> </u>					
7							

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			

		1	
		ł	
Examiner Signature	Date Considered	1	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.